脂质体包插两性霉素B治疗实验性皮肤利什曼病
Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B.
作者信息
Panosian C B, Barza M, Szoka F, Wyler D J
出版信息
Antimicrob Agents Chemother. 1984 May;25(5):655-6. doi: 10.1128/AAC.25.5.655.
Abstract
The therapeutic efficacy of a liposomal preparation of amphotericin B was evaluated in two murine models of cutaneous leishmaniasis. No significant decrease in tissue parasite density was observed in C57BL/6 mice after systemic treatment instituted seven days after footpad inoculation with Leishmania tropica; in contrast, BALB/c mice showed a modest response.
摘要
两性霉素B脂质体制剂的治疗效果在两种皮肤利什曼病小鼠模型中进行了评估。在用热带利什曼原虫对足垫进行接种7天后进行全身治疗，C57BL/6小鼠的组织寄生虫密度没有显著降低；相比之下，BALB/c小鼠有适度反应。
相似文献
1
Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B.脂质体包插两性霉素B治疗实验性皮肤利什曼病
Antimicrob Agents Chemother. 1984 May;25(5):655-6. doi: 10.1128/AAC.25.5.655.
2
Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.脂质体两性霉素B对实验性皮肤利什曼病的活性。
Antimicrob Agents Chemother. 1997 Apr;41(4):752-6. doi: 10.1128/AAC.41.4.752.
3
Biodistribution and Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl--Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.1,2-二油酰基-琥珀酰基-β-甘油磷酰胆碱脂质体插层两性霉素 B 的体内分布和抗利什曼原虫活性。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.02525-16. Print 2017 Sep.
4
Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.两性霉素B-阿拉伯半乳聚糖水溶性衍生物对实验性利什曼病的有效治疗
Antimicrob Agents Chemother. 1999 Sep;43(9):2209-14. doi: 10.1128/AAC.43.9.2209.
5
Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis.KY62对亚马逊利什曼原虫和杜氏利什曼原虫在实验性小鼠皮肤利什曼病和内脏利什曼病中的疗效。
Antimicrob Agents Chemother. 1998 Oct;42(10):2542-8. doi: 10.1128/AAC.42.10.2542.
6
Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model.两性霉素B新脂质体制剂在小鼠模型中对两株婴儿利什曼原虫的活性
Antimicrob Agents Chemother. 1997 Aug;41(8):1731-4. doi: 10.1128/AAC.41.8.1731.
7
Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod.旧世界利什曼原虫皮肤利什曼病对脂质体两性霉素 B 无反应，用局部咪喹莫特治疗。
Pediatr Infect Dis J. 2012 Jan;31(1):97-100. doi: 10.1097/INF.0b013e31822dfbf7.
8
Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice.脂质体包插两性霉素B治疗小鼠系统性念珠菌病的疗效
Antimicrob Agents Chemother. 1984 Aug;26(2):170-3. doi: 10.1128/AAC.26.2.170.
9
Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.开发一种局部的两性霉素 B 脂质体制剂，用于治疗皮肤利什曼病。
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:156-165. doi: 10.1016/j.ijpddr.2019.09.004. Epub 2019 Sep 23.
10
Viscerotropic growth pattern of Leishmania tropica in BALB/c mice is suggestive of a murine model for human viscerotropic leishmaniasis.热带利什曼原虫在BALB/c小鼠中的嗜内脏生长模式提示了一种人类嗜内脏利什曼病的小鼠模型。
Korean J Parasitol. 2007 Dec;45(4):247-53. doi: 10.3347/kjp.2007.45.4.247.
引用本文的文献
1
Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicity.两性霉素B释放速率是脂质体双层中药物状态与毒性之间的联系。
Asian J Pharm Sci. 2022 Jul;17(4):544-556. doi: 10.1016/j.ajps.2022.04.007. Epub 2022 Jun 8.
2
Monocyte subpopulations as important biomarkers of resistence and susceptibility during experimental infection with Leishmania (Leishmania) major.单核细胞亚群作为实验感染利什曼原虫（Leishmania）主要种时耐药性和易感性的重要生物标志物。
Biomed Pharmacother. 2018 Nov;107:1530-1539. doi: 10.1016/j.biopha.2018.08.154. Epub 2018 Sep 5.
3
Discovery, Semisynthesis, Antiparasitic and Cytotoxic Evaluation of 14-Membered Resorcylic Acid Lactones and Their Derivatives.发现、半合成、抗寄生虫和细胞毒性评价 14 元重排贝壳杉烯酸内酯及其衍生物。
Sci Rep. 2017 Sep 18;7(1):11822. doi: 10.1038/s41598-017-12336-0.
4
Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.口服阿奇霉素及其与米替福新联合用药治疗实验性旧大陆皮肤利什曼病
J Parasit Dis. 2016 Jun;40(2):475-84. doi: 10.1007/s12639-014-0529-0. Epub 2014 Aug 31.
5
Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs.抗寄生虫药物给药系统开发中的制剂与生物制药问题
Parasitol Res. 2003 Jun;90 Suppl 2:S63-70. doi: 10.1007/s00436-002-0769-2. Epub 2002 Dec 11.
6
Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B.两性霉素B乙醇制剂对小鼠皮肤利什曼病的有效局部治疗。
Antimicrob Agents Chemother. 1998 Dec;42(12):3092-6. doi: 10.1128/AAC.42.12.3092.
7
Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.脂质体两性霉素B对实验性皮肤利什曼病的活性。
Antimicrob Agents Chemother. 1997 Apr;41(4):752-6. doi: 10.1128/AAC.41.4.752.
8
Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.婴儿利什曼原虫所致内脏利什曼病的治疗：两性霉素B脂质体疗效的实验评估
Antimicrob Agents Chemother. 1996 May;40(5):1214-8. doi: 10.1128/AAC.40.5.1214.
9
Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.脂质体包裹两性霉素B在仓鼠和猴子体内的抗利什曼原虫活性
Antimicrob Agents Chemother. 1986 Dec;30(6):847-51. doi: 10.1128/AAC.30.6.847.
10
Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.脂质组成和脂质体大小对脂质体包插两性霉素B的毒性及体外杀真菌活性的影响
Antimicrob Agents Chemother. 1987 Mar;31(3):421-9. doi: 10.1128/AAC.31.3.421.
本文引用的文献
1
Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes.两性霉素及其他包裹于脂质体中的抗真菌药物的抗利什曼原虫活性。
J Antimicrob Chemother. 1981 Nov;8(5):371-81. doi: 10.1093/jac/8.5.371.
2
Amphotericin B in liposomes: a novel therapy for histoplasmosis.脂质体两性霉素B：一种治疗组织胞浆菌病的新疗法。
Am Rev Respir Dis. 1982 May;125(5):610-1. doi: 10.1164/arrd.1982.125.5.610.
3
Treatment of murine cryptococcosis with liposome-associated amphotericin B.脂质体两性霉素B治疗小鼠隐球菌病
J Infect Dis. 1982 May;145(5):748-52. doi: 10.1093/infdis/145.2.748.
4
Comparative properties and methods of preparation of lipid vesicles (liposomes).脂质囊泡（脂质体）的比较性质及制备方法
Annu Rev Biophys Bioeng. 1980;9:467-508. doi: 10.1146/annurev.bb.09.060180.002343.
5
Strategies in the treatment of systemic fungal infections.系统性真菌感染的治疗策略。
N Engl J Med. 1980 Jan 17;302(3):145-55. doi: 10.1056/NEJM198001173020304.
6
The treatment of kala-azar--new approaches to an old problem.
Indian J Med Res. 1981 Jan;73 Suppl:1-18.
7
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.脂质体包裹两性霉素B对小鼠白色念珠菌播散感染的治疗与预防
J Infect Dis. 1983 May;147(5):939-45. doi: 10.1093/infdis/147.5.939.
8
The chemotherapy of protozoal infections of man.人类原生动物感染的化学疗法。
J Protozool. 1981 Feb;28(1):10-6. doi: 10.1111/j.1550-7408.1981.tb02796.x.
9
Acquired macrophage resistance to in vitro infection with Leishmania.获得性巨噬细胞对利什曼原虫体外感染的抗性。
J Infect Dis. 1983 Dec;148(6):1049-54. doi: 10.1093/infdis/148.6.1049.
10
The chemotherapy of protozoal infections: whither?
J Protozool. 1981 Feb;28(1):30-5. doi: 10.1111/j.1550-7408.1981.tb02800.x.
Zotero 插件